von Willebrand factor (VWF) ristocetin cofactor activity (VWF:RCo) by platelet aggregometry has been considered the gold standard for evaluating the ability of VWF to bind platelets for over 40 years. Many automated systems no longer require platelets and rather rely on agglutination of latex particles. Automated methods of measuring VWF activity have improved performance characteristics and are performed on the same coagulation instruments used for routine testing via immunoturbidimetric methodology. Alternatively, a newer chemiluminescence assay system for measuring VWF activity demonstrates excellent performance characteristics. As these methods are becoming widely used, it is important to assess their performance in diagnosing and monitoring different types of von Willebrand disease. We review the automated methodologies and the published performance of these VWF assays. Advantages and limitations of these automated methods are discussed.
VWD have discordantly low VWF activity compared to VWF antigen.
VWF also binds factor VIII and protects it from degradation, and specific defects in this function causes type 2N VWD with a discordantly low factor VIII procoagulant activity compared to VWF antigen. 2 Numerous "activity" assays that have been developed to reflect the various functions of VWF to bind platelets, collagen, and factor VIII. VWF collagen binding activity (VWF:CB) is highly sensitive to loss of HMW VWF and has been reviewed previously. 3 The most widely used VWF activity assays assess the ability of VWF to bind the GPIb receptor on platelets. Nomenclature for VWF activity assay methodologies has been established as follows: (1) assays based on platelets and ristocetin reagents are termed VWF:RCo, (2) assays based on antibody directed at the GPIb-binding site on VWF are termed VWF:
Ab, (3) assays based on wildtype GPIb and ristocetin are termed VWF:
GPIbR, and (4) assays based on the GPIb containing gain-of-function mutations are termed VWF:GPIbM. 4 This review focuses on automated VWF activity assays (Table 1 ) available on automated coagulation instruments or the ACL Acustar (IL, Bedford, Massachusetts).
| VWF:RCO HISTORY
Prior to the early 1970s, VWD was recognized as an inherited bleeding disorder with prolonged bleeding time, low factor VIII-related antigen (ie, VWF antigen), low factor VIII procoagulant activity, and decreased platelet adherence to glass bead columns. A series of observations and experiments led to the development of the first quantitative assay for VWF activity, known as VWF ristocetin cofactor (VWF:RCo). Ristocetin was used as an antibiotic until it was shown to induce thrombocytopenia by a direct action on platelets in a concentration dependent manner. 5 This effect of inducing aggregation was diagnostically useful in the form of ristocetin induced platelet aggregation (RIPA) and was able to separate some VWD from normal. [6] [7] [8] However, RIPA was not sensitive to mild VWD at the minimum concentration of ristocetin (ie, 1.2 mg/mL) that induced aggregation in all normal donors, so there was a need for improved diagnostic tests. 9 The observation that normal plasma could correct the absence of ristocetin induced aggregation led to the recognition that VWD was a plasma defect rather than the platelet defect. 7, 8 In the early to mid-1970s, methods were developed to quantitate VWF:RCo. Using patient plasma as the source of VWF and washed normal donor platelets 10 or gel filtered platelets 9 as reagent, aggregation studies were able to quantify VWF activity. Over the next 20 years, VWF:RCo along with VWF:Ag assay, factor VIII procoagulant activity, and VWF multimer analysis was used to elucidate the heterogeneity of VWD.
| VWF:RCO BY AGGREGOMETRY
VWF:RCo measured by platelet aggregation or agglutination is considered the gold standard activity assay by which the international reference standard values and VWF concentrate potencies are assigned.
The cationic charge of the ristocetin molecule causes VWF to unfold its tertiary structure and exposes the VWF GPIb binding domain. VWF in the test plasma then aggregates the reagent platelets, which is detected by increased light transmittance.
VWF:RCo is labor intensive and suffers from lack of standardization and poor performance at low values. The aggregometer-based procedures require manual dilutions and construction of a standard curve for each batch of tests. Despite the fact that VWF:RCo has been considered the gold standard, a lack of standardization of instruments, platelets (ie, washed, paraformaldehyde-fixed, lyophilized), ristocetin concentration, and plasma dilutions creates alarming variability across laboratories. The North American Specialized Laboratory Association (NASCOLA), an external quality assurance provider, found the interlaboratory coefficient of variation (CV) to be 28% for the VWF:
RCo assay. 11 Although early aggregometry based methods described a reasonable analytical measurement range of 3% to 50%, 9 the sigmoidal relationship of VWF to aggregation/agglutination required additional dilutions to measure normal and elevated levels. In current practice, the limit of detection is often 10 IU/dL to 20 IU/dL. 12 A study by the College of American Pathologists reported good accuracy for VWF:RCo at lower VWF levels, yet the interlaboratory variation was high (CV = 30%), suggesting poor precision at lower levels of VWF:RCo. 13 Poor precision at low values creates diagnostic uncertainty for all VWD types. the original reference center VWF:RCo and between study sites using the VWF:GPIbR. Intra-assay and inter-assay CV with normal and low controls ranged from 2.3% to 6.3%. While most diagnostic subtypes agreed with the reference center diagnosis, 5% (4/80) of the VWF:GPIbR/VWF:Ag ratios were discrepant, including type 1 VWD (n = 1), type 2A (n = 2), and AVWS (n = 1) samples. 18 In another study, VWD was more extensively subtyped with molecular sequencing and multimeric substructure. 16 The impressive sensitivity to low VWF levels and high precision make the ACL AcuStar system a potentially impactful option for the future, especially since VWF:Ag, VWF:GPIbR, and VWF:CB may be available on the same system. Several studies have evaluated the clinical utility of VWF:Ab activity as a screen/initial evaluation. [24] [25] [26] [27] One study found 100% sensitivity and 85% specificity for VWD using a cutoff of ≤60% VWF:
| AUTOMATED VWF:RCO
Ab and/or a ratio of <0.7, and implementation of this criteria would have prevented 67% of the VWF:RCo testing. 24 Another study used an arbitrary cutoff of 50 IU/dL in consecutive patients seen for VWD evaluation and found a lower sensitivity of 75% and a higher specificity of 95% for VWF:Ab alone on a STA-R coagulation instrument;
however, sensitivity and specificity were almost identical for VWF:
RCo alone. 27 The reason for the lower sensitivity compared to earlier Siemens instruments and a Stago instrument. [30] [31] [32] [33] Good correlation was demonstrated between VWF:GPIbM and VWF:RCo, and the mean difference between methods was 6 IU/dL to 7 IU/dL lower by VWF Ac Innovance. Analytical performance characteristics were most extensively evaluated for Sysmex coagulation instruments. 32 At near normal values (127 U/dL), the between-run precision was 4.1% (2.2%-6.2%) across the entire series of Sysmex instruments. At low values (9 U/dL), the between-run precision was 3.4% (1.8%-6.6%).
The measurement range was 4 U/dL to 600 U/dL on most instruments, and the limit of detection was 2.2 U/dL for all systems. were categorized concordantly with the reference center's VWF:RCo using a cutoff ratio of <0.7. 30 In contrast, a group using aggregometry VWF:RCo, found a discrepant diagnostic classification in 41% (22/66) of VWD using a locally developed ratio cutoff of 0.63 for VWF:GPIbM. The discrepancies were mainly due to lower VWF:GPIbM/VWF:Ag ratios resulting in the diagnosis of more qualitative (type 2) VWD. The lower limit of the measurement range for VWF:RCo was 10 IU/dL, hence, the improved lower limit of measurement (4 IU/dL) and improved precision (CV = 9.4%, abnormal control) with the VWF:GPIbM assay allowed better discrimination of activity to antigen ratio compared to VWF:RCo (CV = 14.5%, abnormal control). 31 
| MONITORING THERAPY
Evidence is also mounting that automated VWF activity assays are VWF activity assays has not been assessed.
| ACQUIRED VON WILLEBRAND SYNDROME (AVWS)
Automated VWF activity is useful in the detection of AVWS as well as inherited VWD.
In contrast to the findings from external quality assurance data 
| GENERAL DIAGNOSTIC CONSIDERATIONS
Many caveats of laboratory testing for VWD apply equally to VWF:
RCo and newer automated VWF activity assays (Supporting Information Table S1 ). Like VWF:RCo, the newer automated VWF activity methods are affected by ABO blood group, with 25% lower values in the blood group O population, so blood group O patients must be represented in the reference interval study, as appropriate. Elevation of VWF in response to stress, exercise, exogenous estrogen, and pregnancy are confounding issues for all VWF assays. VWF activity alone may be elevated into the reference interval but the VWF activity/VWF antigen ratio or factor VIII/VWF:Ag ratio could provide evidence of type 2 VWD or AVWS. VWF:RCo and automated VWF activity used alone may miss up to 25% of VWD 27 ; therefore, VWF activity, VWF:
Ag, and factor VIII should be performed together, as recommended by the ISTH-SSC guideline. 2 Moreover, repeat testing and VWF:CB assay are recommended to reduce errors caused by preanalytical issues and variability in assay performance. 
| VWD SUBCLASSIFICATION AND VWF ACTIVITY
Interesting discrepancies in activity assays may be related to the genotypic heterogeneity of VWD and VWF activity methodology. For example, VWF:Ab activity was significantly higher than VWF:RCo in three patients from the same family with type 2 M VWD and p.
G1324A. 27 This mutation is associated with enhanced stability and slow unfolding of A1 domain during exposure to shear stress rather than the typical destabilized A1 domain associated with mutations causing direct inhibition of GPIb binding. 37 The How is von Willebrand factor activity measured in the laboratory?
For over 40 years, the VWF ristocetin cofactor activity (VWF:RCo), which measures the ability of VWF to agglutinate platelets in the presence of ristocetin, has been the "gold standard". The manual aggregometry methodology is labor intensive and has many limitations, including lack of standardization with high inter-laboratory CV, only a moderate lower level of detection, and less sensitivity for detecting acquired von Willebrand syndrome. While the automated VWF:RCo improves precision, the lower limit of detection is not significantly improved. Modifications to the automated VWF:RCo methodology, newer automated methods using latex beads (rather than platelets), or chemiluminescent methods improve performance and increase sensitivity for certain subtypes of VWD. 41, 42 These new tests are gaining acceptance and may eventually replace the long-standing VWF:RCo performed by aggregometry in many laboratories.
What are the reference intervals for von Willebrand?
Reference intervals vary based on the ABO blood group of a patient.
VWF is modified by the same glycosyltransferases that determine the ABO blood group, and the carbohydrate content impacts VWF proteolysis and clearance. VWF levels are the highest in blood group AB and lowest in blood group O (AB > A > B > O).
40
Is there any additional testing which aids in the diagnosis of von Willebrand Disease?
The initial diagnostic testing should include VWF antigen, VWF ristocetin cofactor activity, and factor VIII. VWF ristocetin cofactor activity should not be used alone because it is elevated as part of an acute phase reaction. As reported in the literature, the sensitivity of the activity assays and the VWF activity to VWF antigen ratio cutoff can influence the sensitivity and specificity. While many assays are quite sensitive at detecting most common types of VWD, the rare subtypes (eg, type 3, type 2M, and severe type 1)
can be difficult to classify. VWD disease classification can require additional testing as indicated by screening results, clinical suspicion, and family history. Additional testing for definitive subtyping can include ristocetin induced platelet aggregation (RIPA), VWF collagen binding, VWF multimer analysis, VWF propeptide, and VWF gene analysis. 41, 42 Are there patient conditions/comorbidities which may impact the testing?
VWF is elevated during acute phase reactions, so it is important interpret results in the setting of a patient's state of health. Exogenous estrogen use, pregnancy, and exercise increase VWF levels, and laboratory testing results could appear normal or elevated in such situations. 40 Finally, VWF classification should not be performed following therapeutic treatment for an acute bleed, including recent transfusions, DDAVP, or VWF replacement therapy.
